Acquired dysfibrinogenemia secondary to multiple myeloma

Acta Haematologica

Volumn 120, Issue 2, 2008, Pages 75-81

  Kotlín, Roman ^a   Sobotková, Alžběta ^a   Riedel, Tomáš ^a   Salaj, Peter ^a   Suttnar, Jiří ^a   Reicheltová, Zuzana ^a   Májek, Pavel ^a   Khaznadar, Tarek ^a   Dyr, Jan E ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

Author keywords

Acquired dysfibrinogenemia; Amorphous clot; Fibrinogen; Multiple myeloma; Paraprotein

Indexed keywords

BATROXOBIN; FIBRIN; FIBRINOGEN; FIBRINOPEPTIDE; MELPHALAN; PARAPROTEIN; PREDNISONE;

AGED; ARTICLE; CASE REPORT; DNA SEQUENCE; DYSFIBRINOGENEMIA; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOBLOTTING; MALE; MASS SPECTROMETRY; MULTIPLE MYELOMA; PARTIAL THROMBOPLASTIN TIME; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTHROMBIN TIME; SCANNING ELECTRON MICROSCOPY; THROMBIN TIME;

AFIBRINOGENEMIA; AGED; BLOOD COAGULATION TESTS; FIBRIN; FIBRINOGEN; HUMANS; MALE; MICROSCOPY, ELECTRON, SCANNING; MULTIPLE MYELOMA; PARAPROTEINS; PEPTIDE FRAGMENTS; TREATMENT OUTCOME;

EID: 54749153706     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000160182     Document Type: Article

References (36)

1. Maniatis A: Pathophysiology of paraprotein production. Ren Fail 1998;20:821-828.
2. DiMinno G, Coraggio F, Cerbone AM, Capitanio AM, Manzo C, Spina M, Scarpato P, Dattoli GM, Mattioli PL, Mancini M: A myeloma paraprotein with specifity for platelet glycoprotein IIIa in a patient with a fatal bleeding disorder. J Clin Invest 1986;77:157-164.
3. Hoots WK, Carrell NA, Wagner RH, Cooper HA, McDonagh J: A naturally occurring antibody that inhibits fibrin polymerization. N Engl J Med 1981;304:857-861.
4. Ruiz-Arguelles A: Spontaneous reversal of acquired autoimmune dysfibrinogenemia probably due to an anti-idiotypic antibody directed to an interspecies cross-reactive idiotype expressed on antifibrinogen antibodies. J Clin Invest 1988;82:958-963.
5. Rosenberg RD, Colman RW, Lorand L: A new haemorrhagic disorder with defective fibrin stabilization and cryofibrinogenaemia. Br J Haematol 1974;26:269-284.
6. Marciniak R, Greenwood MF: Acquired coagulation inhibitor delaying fibrinopeptide release. Blood 1979;53:81-92.
7. Levy J, Pettei MJ, Weitz JI: Dysfibrinogenemia in obstructive liver disease. J Pediatr Gastroenterol Nutr 1987;6:967-970.
8. Martinez J, MacDonald KA, Palascak JE: The role of sialic acid in the dysfibrinogenemia associated with liver disease: distribution of sialic acid on the constituent chains. Blood 1983;61:1196-1202.
9. Maak B, Meyer M, Dietze H: Acquired dysfibrinogenemia in a child in the course of a liver disease. Monatsschr Kinderheilkd 1990;138:446-450.
10. Reganon E, Vila V, Aznar J, Garrido G, Estelles A, Berenguer J: Study of the formation of fibrin clot in cirrhotic patients. An approach to study of acquired dysfibrinogenemia, Thromb Res 1987;46:705-714.
11. Narviaza MJ, Fernandez J, Cuesta B, Paramo JA, Rocha E: Role of sialic acid in acquired dysfibrinogenemia associated with liver cirrhosis. Ric Clin Lab 1986;16:563-568.
12. Bohler A, Redondo M, Lämmle B: Verlängerte Thrombinzeit bei einem Patienten mit multiplem Myelom. Ther Umsch 1999;56:491-494.
13. Carr ME, Zekert SL: Abnormal clot retraction, altered fibrin structure, and normal platelet function in multiple myeloma. Am J Physiol 1994;266:H1195-H1201.
14. Saif MW, Allegra CJ, Greenberg B: Bleeding diathesis in multiple myeloma. J Hematother Stem Cell Res 2001;10:657-660.
15. Lackner H, Hunt V, Zucker MB, Pearson J: Abnormal fibrin ultrastructure, polymerization, and clot retraction in multiple myeloma. Br J Haematol 1970;18:625-636.
16. Gralnick HR, Givelber H, Abrams E: Dysfibrinogenemia associated with hepatoma. N Engl J Med 1978;299:221-226.
17. Ballard JO, Kelly GA, Kukrika MD, Sanders JC, Eyster ME: Acquired dysfibrinogenemia in a hemophiliac with hepatoma: resolution of fibrinogen dysfunction following chemotherapy. Cancer 1981;48:686-690.
18. Dawson NA, Barr CF, Alving BM: Acquired dysfibrinogenemia. Paraneoplastic syndrome in renal cell carcinoma. Am J Med 1985;78:682-686.
19. Kwaan HC, Levin M, Sakurai S, Kucuk O, Rooney MW, Lis LJ, Kauffman JW: Digital ischemia and gangrene due to red blood cell aggregation induced by acquired dysfibrinogenemia. J Vasc Surg 1997;26:1061-1068.
20. Aurousseau MH, Levacher S, Bénéton C, Blaise M, Pourrait JL: Dysfibrinogénémie et thrombocytopénie transitoires associées à une pancréatite aiguë récidivante lors d'un traitement par l'isotrétinoïne. Rev Méd Interne 1995;16:622-625.
21. Ashby MA, Lazarchick J: Case report: acquired dysfibrinogenemia secondary to mithramycin toxicity. Am J Med Sci 1986;292:53-55.
22. Mori T, Murata M, Wakui M, Muto A, Ishida A, Tanosaki R, Okamoto S, Ikeda Y: Acquired dysfibrinogenemia following allogenic bone marrow transplantation. Am J Hematol 1997;56:294-295.
23. Shigekiyo T, Kosaka M, Shintani Y, Azuma H, Iishi Y, Saito S: Inhibition of fibrin monomer polymerization by Bence Jones protein in a patient with primary amyloidosis. Acta Haematol 1989;81:160-165.
24. Dear A, Brennan SO, Sheat MJ, Faed JM, George PM: Acquired dysfibrinogenemia caused by monoclonal production of immunoglobulin λ light chain. Haematologica 2007;92:e111-e117.
25. Sugai S: IgA pyroglobulin, hyperviscosity syndrome and coagulation abnormality in a patient with multiple myeloma. Blood 1972;39:224-237.
26. Gabriel DA, Smith LA, Folds JD, Davis L, Cancelosi SE: The influence of immunoglobulin (IgG) on the assembly of fibrin gels. J Lab Clin Med 1983;101:545-552.
27. O'Kane MJ, Wisdom GB, Desai ZR, Archbold GPR: Inhibition of fibrin monomer polymerization by myeloma immunoglobulin. J Clin Pathol 1994;47:266-268.
28. Panzer S, Thaler E: An acquired cryoglobulinemia which inhibits fibrin polymerization in a patient with IgG kappa myeloma. Haemostasis 1993;23:69-76.
29. Brennan SO, Hammonds B, George PM: Aberrant hepatic processing causes removal of activation peptide and primary polymerization site from fibrinogen Canterbury (Aα Val → Asp). J Clin Invest 1995;96:2854-2858.
30. Kotlín R, Chytilová M, Suttnar J, Salaj P, Riedel T, Šantrůček J, Klener P, Dyr JE: A novel fibrinogen variant - Praha I: hypofibrinogenemia associated with γ 351 Gly → Ser substitution. Eur J Haematol 2007;78:410-416.
31. Suttnar J, Dyr JE, Fořtová H, Pristach J: Determination of fibrinopeptides by high performance liquid chromatography. Biochem Clin Bohemoslov 1989;18:17-25.
32. Kotlín R, Chytilová M, Suttnar J, Riedel T, Salaj P, Blatný J, Šantrůček J, Klener P, Dyr JE: Fibrinogen Nový Jičín and Praha II: cases of hereditary Aalpha 16 Arg → Cys and Aalpha 16 Arg → His dysfibrinogenemia. Thromb Res 2007;121:75-84.
33. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-685.
34. Scheiner T, Jiroušková M, Nagaswami C, Coller BS, Weisel JW: A monoclonal antibody to the fibrinogen gamma-chain alters fibrin clot structure and its properties by producing short, thin fibers arranged in bundles. J Thromb Haemost 2003;1:2594-2602.
35. Yang Z, Mochalkin I, Doolittle RF: A model of fibrin formation based on crystal structures of fibrinogen and fibrin fragments complexed with synthetic peptides. Proc Natl Acad Sci USA 2000;97:14156-14161.
36. Smith E, Kochwa S, Wasserman LR: Aggregation of IgG globulin in vivo. The hyperviscosity syndrome in multiple myeloma. Am J Med 165;39:35-48.